RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of ...
Optimizing iPSC differentiation significantly improves in vitro Alzheimer's disease models, leading to more accurate and ...
PSC-derived cells and micro-physiological systems provide significant advancements in enhancing neuronal disease models, ...
could then be coaxed to differentiate into different cell types. Fifteen years on, iPSC technology has become the basis for many drug development efforts, and it could one day change the outlook ...
This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases. Advancing Cell ...
How are induced pluripotent stem (iPS) cells different from embryonic stem (ES) cells? What can we use iPS cells for? ES cells were originally derived from the inner cell mass (ICM) or epiblast of ...
A new era of cell therapy has well and truly arrived with the iPSC field setting a trailblazing fire with its potential to develop fully scalable, off-the-shelf cell lines reducing the cost of ...
ExCellerate iPSC Expansion Medium is specifically formulated for the in vitro, feeder-free expansion of human pluripotent stem cells, including embryonic stem (ES) and induced pluripotent stem (iPS) ...
iPS cells are being used to treat eye diseases to address donor shortages. We explore advancements made in Japan, such as the transplantation of iPS cell-derived corneal cells and retinal sheets.
This research group has developed a robot/AI system that automatically performs trial-and-error to examine the optimum conditions for culturing iPS cells, and has ...
U sing iPS cells generated from a patient with a myeloid neoplasm caused by a rare chromosomal rearrangement between the ...
Japan’s first clinical trial using induced pluripotent stem (iPS) cells to treat cancer patients is expected to start in August, raising hopes for a breakthrough against the leading cause of ...